Exploiting drug-induced senescence in transgenic mouse models

Beyond Apoptosis: Cellular Outcomes of Cancer Therapy

Volumn , Issue , 2008, Pages 273-294

  Kilic, Mehtap ^a   Schmitt, Clemens A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84903723053     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (101)

1. Spruck CH 3rd, Gonzalez-Zulueta M, Shibata A, et al. p16 gene in uncultured tumours. Nature 1994; 370(6486):183-184.
2. Carter TL, Reaman GH, Kees UR. INK4A/ARF deletions are acquired at relapse in childhood acute lymphoblastic leukaemia: a paired study on 25 patients using realtime polymerase chain reaction. Br J Haematol 2001; 113(2):323-328.
3. Calero Moreno TM, Gustafsson G, Garwicz S, et al. Deletion of the Ink4-locus (the p16ink4a, p14ARF and p15ink4b genes) predicts relapse in children with ALL treated according to the Nordic protocols NOPHO-86 and NOPHO-92. Leukemia 2002; 16(10):2037-2045.
4. Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 2000; 6(9):1029-1035.
5. Phillips RM, Bibby MC, Double JA. A critical appraisal of the predictive value of in vitro chemosensitivity assays. J Natl Cancer Inst 1990; 82(18):1457-1468.
6. Nara N, Suzuki T, Nagata K, et al. Relationship between the in vitro sensitivity to cytosine arabinoside of blast progenitors and the outcome of treatment in acute myeloblastic leukaemia patients. Br J Haematol 1988; 70(2):187-191.
7. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69(1):119-128.
8. de Stanchina E, McCurrach ME, Zindy F, et al. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 1998; 12(15):2434-2442.
9. Zindy F, Eischen CM, Randle DH, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998; 12(15):2424-2433.
10. Serrano M. The tumor suppressor protein p16INK4a. Exp Cell Res 1997; 237(1):7-13.
11. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73(8):2013-2026 (published erratum appears in Cancer 1994; 73(12):3108).
12. Schmitt CA, McCurrach ME, De Stanchina E, et al. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999; 13(20):2670-2677.
13. Strasser A, Harris AW, Bath ML, et al. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990; 348(6299):331-333.
14. Eischen CM, Roussel MF, Korsmeyer SJ, et al. Bax loss impairs Myc-Induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol Cell Biol 2001; 21(22):7653-7662.
15. Schmitt CA, Yang M, Fridman JS, et al. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002; 1(3):289-298.
16. Serrano M, Lin AW, McCurrach ME, et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88(5):593-602.
17. Zhu J, Woods D, McMahon M, et al. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 1998; 12(19):2997-3007.
18. Mason DX, Jackson TJ, Lin AW. Molecular signature of oncogenic ras-induced senescence. Oncogene 2004; 23(57):9238-9246.
19. Shelton DN, Chang E, Whittier PS, et al. Microarray analysis of replicative senescence. Curr Biol 1999; 9(17):939-945.
20. Lundberg AS, Hahn WC, Gupta P, et al. Genes involved in senescence and immortalization. Curr Opin Cell Biol 2000; 12(6):705-709.
21. Collado M, Serrano M. The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 2006; 6(6):472-476.
22. Kurz DJ, Decary S, Hong Y, et al. Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci 2000; 113(pt 20):3613-3622.
23. Beausejour CM, Krtolica A, Galimi F, et al. Reversal of human cellular senescence:roles of the p53 and p16 pathways. EMBO J 2003; 22(16):4212-4222.
24. Narita M, Nunez S, Heard E, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003; 113(6):703-716.
25. Zhang R, Poustovoitov MV, Ye X, et al. Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell 2005; 8(1):19-30.
26. Narita M, Narita M, Krizhanovsky V, et al. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 2006; 126(3):503-514.
27. Sherr CJ, DePinho RA. Cellular senescence: mitotic clock or culture shock? Cell 2000; 102(4):407-410.
28. Lazzerini Denchi E, Attwooll C, Pasini D, et al. Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol Cell Biol 2005; 25(7):2660-2672.
29. Braig M, Lee S, Loddenkemper C, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005; 436(7051):660-665.
30. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436(7051):725-730.
31. Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in premalignant tumours. Nature 2005; 436(7051):642.
32. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436(7051):720-724.
33. Liang XH, Jackson S, Seaman M, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999; 402(6762):672-676.
34. Lum JJ, Bauer DE, Kong M, et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005; 120(2):237-248.
35. Boya P, Gonzalez-Polo RA, Casares N, et al. Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 2005; 25(3):1025-1040.
36. Qu X, Yu J, Bhagat G, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003; 112(12):1809-1820.
37. Denko NC, Giaccia AJ, Stringer JR, et al. The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc Natl Acad Sci U S A 1994; 91(11):5124-5128.
38. Tanaka S, Diffley JF. Deregulated G1-cyclin expression induces genomic instability by preventing efficient pre-RC formation. Genes Dev 2002; 16(20):2639-2649.
39. Vafa O, Wade M, Kern S, et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 2002; 9(5):1031-1044.
40. Pusapati RV, Rounbehler RJ, Hong S, et al. ATM promotes apoptosis and suppresses tumorigenesis in response to Myc. Proc Natl Acad Sci U S A 2006; 103(5):1446-1451.
41. Di Micco R, Fumagalli M, Cicalese A, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444(7119):638-642.
42. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anticancer barrier in early human tumorigenesis. Nature 2005; 434(7035):864-870.
43. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434(7035):907-913.
44. Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444(7119):633-637.
45. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev 2007; 21(1):43-48.
46. Lowe SW, Ruley HE, Jacks T, et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74(6):957-967.
47. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266(5186):807-810.
48. Schmitt CA. Senescence, apoptosis and therapy - cutting the lifelines of cancer. Nat Rev Cancer 2003; 3(4):286-295.
49. Chang BD, Broude EV, Dokmanovic M, et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 1999; 59(15):3761-3767.
50. Chang BD, Xuan Y, Broude EV, et al. Role of p53 and p21waf1/cip1 in senescencelike terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 1999; 18(34):4808-4818.
51. Han Z, Wei W, Dunaway S, et al. Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J Biol Chem 2002; 277(19):17154-17160.
52. Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol 1999; 187(1):127-137.
53. Lee S, Schmitt CA. Mouse Models in Cancer Research. Germany: Wiley-VCH, 2006.
54. Palmiter RD. Transgenic mice-the early days. Int J Dev Biol 1998; 42(7):847-854.
55. Jonkers J, Berns A. Conditional mouse models of sporadic cancer. Nat Rev Cancer 2002; 2(4):251-265.
56. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001; 410(6832):1111-1116.
57. Meuwissen R, Linn SC, van der Valk M, et al. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene 2001; 20(45):6551-6558.
58. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abltransduced bone marrow. Blood 1998; 92(10):3780-3792.
59. Hemann MT, Fridman JS, Zilfou JT, et al. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet 2003; 33(3):396-400.
60. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445(7128):656-660.
61. Nagano M, Brinster CJ, Orwig KE, et al. Transgenic mice produced by retroviral transduction of male germ-line stem cells. Proc Natl Acad Sci U S A 2001; 98(23):13090-13095.
62. Carmell MA, Zhang L, Conklin DS, et al. Germline transmission of RNAi in mice. Nat Struct Biol 2003; 10(2):91-92.
63. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354(5):496-507.
64. Lyons SK. Advances in imaging mouse tumour models in vivo. J Pathol 2005; 205(2):194-205.
65. Lyons SK, Meuwissen R, Krimpenfort P, et al. The generation of a conditional reporter that enables bioluminescence imaging of Cre/loxP-dependent tumorigenesis in mice. Cancer Res 2003; 63(21):7042-7046.
66. Edinger M, Cao YA, Hornig YS, et al. Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur J Cancer 2002; 38(16):2128-2136.
67. Hoffman RM, Yang M. Dual-color, whole-body imaging in mice. Nat Biotechnol 2005; 23(7):790; author reply 791.
68. Vooijs M, Jonkers J, Lyons S, et al. Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. Cancer Res 2002; 62(6):1862-1867.
69. Bearss DJ, Subler MA, Hundley JE, et al. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors. Oncogene 2000; 19(8):1114-1122.
70. Barrington RE, Subler MA, Rands E, et al. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol 1998; 18(1):85-92.
71. Smith JB, Wickstrom E. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model. J Natl Cancer Inst 1998; 90(15):1146-1154.
72. Chin L, Tam A, Pomerantz J, et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999; 400(6743):468-472.
73. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999; 4(2):199-207.
74. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318(6046):533-538.
75. Schmitt CA, Wallace-Brodeur RR, Rosenthal CT, et al. DNA damage responses and chemosensitivity in the Em-myc mouse lymphoma model. Cold Spring Harb Symp Quant Biol 2000; 65:499-510.
76. Schmitt CA, Lowe SW. Apoptosis and chemoresistance in transgenic cancer models. J Mol Med 2002; 80:137-146.
77. Eischen CM, Weber JD, Roussel MF, et al. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13(20):2658-2669.
78. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109:335-346.
79. Hsu B, Marin MC, el-Naggar AK, et al. Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis. Oncogene 1995; 11(1):175-179.
80. Schmitt CA, Lowe SW. Bcl-2 mediates chemoresistance in matched pairs of primary Em-myc lymphomas in vivo. Blood Cells Mol Dis 2001; 27(1):206-216.
81. Waldman T, Zhang Y, Dillehay L, et al. Cell-cycle arrest versus cell death in cancer therapy. Nat Med 1997; 3(9):1034-1036.
82. Chang BD, Swift ME, Shen M, et al. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci U S A 2002; 99(1):389-394.
83. Krtolica A, Parrinello S, Lockett S, et al. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A 2001; 98(21):12072-12077.
84. Sage J, Miller AL, Perez-Mancera PA, et al. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 2003; 424(6945):223-228.
85. Bannister AJ, Schneider R, Kouzarides T. Histone methylation: dynamic or static? Cell 2002; 109(7):801-806.
86. Lachner M, O’Carroll D, Rea S, et al. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 2001; 410(6824):116-120.
87. Ait-Si-Ali S, Guasconi V, Fritsch L, et al. A Suv39h-dependent mechanism for silencing S-phase genes in differentiating but not in cycling cells. EMBO J 2004; 23(3):605-615.
88. Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004; 119(7):941-953.
89. Metzger E, Wissmann M, Yin N, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005; 437(7057):436-439.
90. Yamane K, Toumazou C, Tsukada Y, et al. JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell 2006; 125(3):483-495.
91. Klose RJ, Kallin EM, Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet 2006; 7(9):715-727.
92. Shin S, Janknecht R. Diversity within the JMJD2 histone demethylase family. Biochem Biophys Res Commun 2007; 353(4):973-977.
93. Cloos PA, Christensen J, Agger K, et al. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 2006; 442:307-311.
94. Klose RJ, Yamane K, Bae Y, et al. The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature 2006; 442(7100):312-316.
95. Whetstine JR, Nottke A, Lan F, et al. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell 2006; 125(3):467-481.
96. Lindemann RK, Newbold A, Whitecross KF, et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A 2007; 104(19):8071-8076.
97. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428(6980):332-337.
98. Amaravadi RK, Yu D, Lum JJ, et al. Autophagy inhibition enhances therapyinduced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007; 117(2):326-336.
99. Jonkers J, Berns A. Oncogene addiction: sometimes a temporary slavery. Cancer Cell 2004; 6(6):535-538.
100. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445(7128):661-665.
101. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006; 127(7):1323-1334.